Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762.TW)
TWD 28.2
(7.22%)
TWD 28.2
(7.22%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 1.21 Billion TWD | 47.69% |
| 2022 | 819.95 Million TWD | 8.77% |
| 2021 | 753.85 Million TWD | 56.65% |
| 2020 | 481.24 Million TWD | 16.75% |
| 2019 | 412.18 Million TWD | 13.74% |
| 2018 | 362.39 Million TWD | 7.98% |
| 2017 | 335.6 Million TWD | -16.47% |
| 2016 | 401.75 Million TWD | -6.71% |
| 2015 | 430.64 Million TWD | -1.75% |
| 2014 | 438.32 Million TWD | 28.83% |
| 2013 | 340.24 Million TWD | 4.18% |
| 2012 | 326.58 Million TWD | -4.83% |
| 2011 | 343.16 Million TWD | 21.78% |
| 2010 | 281.77 Million TWD | -12.5% |
| 2009 | 322.03 Million TWD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 1.33 Billion TWD | 9.95% |
| 2024 Q2 | 1.15 Billion TWD | -13.26% |
| 2023 Q4 | 1.21 Billion TWD | 9.48% |
| 2023 FY | 1.21 Billion TWD | 47.69% |
| 2023 Q1 | 826.13 Million TWD | 0.75% |
| 2023 Q3 | 1.1 Billion TWD | 31.4% |
| 2023 Q2 | 841.86 Million TWD | 1.9% |
| 2022 Q2 | 725.71 Million TWD | -5.41% |
| 2022 Q1 | 767.25 Million TWD | 1.78% |
| 2022 FY | 819.95 Million TWD | 8.77% |
| 2022 Q4 | 819.95 Million TWD | 7.13% |
| 2022 Q3 | 765.34 Million TWD | 5.46% |
| 2021 Q1 | 501.93 Million TWD | 4.3% |
| 2021 FY | 753.85 Million TWD | 56.65% |
| 2021 Q3 | 710.34 Million TWD | 18.61% |
| 2021 Q4 | 753.85 Million TWD | 6.12% |
| 2021 Q2 | 598.89 Million TWD | 19.32% |
| 2020 Q3 | 482.97 Million TWD | 23.1% |
| 2020 FY | 481.24 Million TWD | 16.75% |
| 2020 Q1 | 398.02 Million TWD | -3.44% |
| 2020 Q2 | 392.33 Million TWD | -1.43% |
| 2020 Q4 | 481.24 Million TWD | -0.36% |
| 2019 Q3 | 329.49 Million TWD | 19.4% |
| 2019 Q4 | 412.18 Million TWD | 25.1% |
| 2019 FY | 412.18 Million TWD | 13.74% |
| 2019 Q1 | 318.93 Million TWD | -11.99% |
| 2019 Q2 | 275.95 Million TWD | -13.48% |
| 2018 Q1 | 322.72 Million TWD | -3.84% |
| 2018 Q4 | 362.39 Million TWD | 3.69% |
| 2018 Q3 | 349.49 Million TWD | 18.11% |
| 2018 FY | 362.39 Million TWD | 7.98% |
| 2018 Q2 | 295.91 Million TWD | -8.31% |
| 2017 Q2 | 439.52 Million TWD | 10.98% |
| 2017 Q4 | 335.6 Million TWD | -18.01% |
| 2017 FY | 335.6 Million TWD | -16.47% |
| 2017 Q3 | 409.31 Million TWD | -6.88% |
| 2017 Q1 | 396.03 Million TWD | -1.42% |
| 2016 Q4 | 401.75 Million TWD | 6.72% |
| 2016 FY | 401.75 Million TWD | -6.71% |
| 2016 Q3 | 376.44 Million TWD | -16.23% |
| 2016 Q2 | 449.35 Million TWD | -2.83% |
| 2016 Q1 | 462.43 Million TWD | 7.38% |
| 2015 FY | 430.64 Million TWD | -1.75% |
| 2015 Q2 | 418.43 Million TWD | -6.03% |
| 2015 Q1 | 445.28 Million TWD | 1.59% |
| 2015 Q4 | 430.64 Million TWD | -6.05% |
| 2015 Q3 | 458.37 Million TWD | 9.54% |
| 2014 Q3 | 470.27 Million TWD | 13.4% |
| 2014 FY | 438.32 Million TWD | 28.83% |
| 2014 Q4 | 438.32 Million TWD | -6.8% |
| 2014 Q2 | 414.71 Million TWD | 5.8% |
| 2014 Q1 | 391.96 Million TWD | 15.2% |
| 2013 Q3 | 389.41 Million TWD | 2.75% |
| 2013 Q4 | 340.24 Million TWD | -12.63% |
| 2013 FY | 340.24 Million TWD | 4.18% |
| 2013 Q1 | 388.32 Million TWD | 18.9% |
| 2013 Q2 | 378.99 Million TWD | -2.4% |
| 2012 FY | 326.58 Million TWD | -4.83% |
| 2012 Q2 | 349.9 Million TWD | -15.0% |
| 2012 Q3 | 348.26 Million TWD | -0.47% |
| 2012 Q4 | 326.58 Million TWD | -6.22% |
| 2012 Q1 | 411.64 Million TWD | 19.96% |
| 2011 Q4 | 343.16 Million TWD | 23.4% |
| 2011 Q2 | 308.11 Million TWD | -5.82% |
| 2011 Q1 | 327.15 Million TWD | 16.1% |
| 2011 FY | 343.16 Million TWD | 21.78% |
| 2011 Q3 | 278.08 Million TWD | -9.75% |
| 2010 FY | 281.77 Million TWD | -12.5% |
| 2010 Q4 | 281.77 Million TWD | 0.0% |
| 2009 FY | 322.03 Million TWD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Apex Biotechnology Corp. | 747.71 Million TWD | -61.964% |
| Sinphar Pharmaceutical Co.,Ltd. | 839.19 Million TWD | -44.308% |
| Panion & Bf Biotech Inc. | 538.09 Million TWD | -125.057% |
| GenMont Biotech Incorporation | 88.11 Million TWD | -1274.323% |
| Abnova (Taiwan) Corporation | 408.3 Million TWD | -196.601% |
| Adimmune Corporation | 526.4 Million TWD | -130.056% |
| Tanvex BioPharma, Inc. | 108.28 Million TWD | -1018.369% |
| Polaris Group | 36.35 Million TWD | -3231.113% |
| Energenesis Biomedical CO.,LTD. | 733 Thousand TWD | -165115.007% |
| UnicoCell Biomed Co., Ltd. | 5.45 Million TWD | -22116.584% |
| PELL Bio-Med Technology Co. Ltd. | 3.76 Million TWD | -32082.461% |